ECSP22056585A - Variantes de alfa-glucosidasa ácida diseñadas por ingeniería - Google Patents

Variantes de alfa-glucosidasa ácida diseñadas por ingeniería

Info

Publication number
ECSP22056585A
ECSP22056585A ECSENADI202256585A ECDI202256585A ECSP22056585A EC SP22056585 A ECSP22056585 A EC SP22056585A EC SENADI202256585 A ECSENADI202256585 A EC SENADI202256585A EC DI202256585 A ECDI202256585 A EC DI202256585A EC SP22056585 A ECSP22056585 A EC SP22056585A
Authority
EC
Ecuador
Prior art keywords
glucosidase
acid alpha
engineered
engineered variants
polypeptides
Prior art date
Application number
ECSENADI202256585A
Other languages
English (en)
Inventor
Ismaili Moulay Alaoui
Chinping Chng
William Hallows
Yu Zhu
Jonathan Vroom
Gjalt Huisman
Rachel Botham
Nikki Dellas
David Homan
Jessica Lao
Adam Silverman
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of ECSP22056585A publication Critical patent/ECSP22056585A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2428—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona polipéptidos de alfa-glucosidasa ácida (GAA) diseñados por ingeniería y composiciones de los mismos. En algunas realizaciones, los polipéptidos de GAA diseñados por ingeniería se han optimizado para proporcionar expresión aumentada, estabilidad a pH neutro y actividad en lisados celulares. La invención también proporciona métodos para la utilización de las composiciones que comprenden los polipéptidos de GAA diseñados por ingeniería para fines terapéuticos y otros fines.
ECSENADI202256585A 2019-12-20 2022-07-19 Variantes de alfa-glucosidasa ácida diseñadas por ingeniería ECSP22056585A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962951625P 2019-12-20 2019-12-20

Publications (1)

Publication Number Publication Date
ECSP22056585A true ECSP22056585A (es) 2022-11-30

Family

ID=76438815

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202256585A ECSP22056585A (es) 2019-12-20 2022-07-19 Variantes de alfa-glucosidasa ácida diseñadas por ingeniería

Country Status (17)

Country Link
US (2) US11970722B2 (es)
EP (1) EP4077679A4 (es)
JP (2) JP7865532B2 (es)
KR (1) KR20220129547A (es)
CN (1) CN115427574A (es)
AR (1) AR120858A1 (es)
AU (1) AU2020408066A1 (es)
BR (1) BR112022011760A2 (es)
CA (1) CA3165484A1 (es)
CL (1) CL2022001655A1 (es)
CO (1) CO2022010224A2 (es)
EC (1) ECSP22056585A (es)
IL (1) IL294082A (es)
MX (1) MX2022007399A (es)
PE (1) PE20221266A1 (es)
TW (1) TWI901622B (es)
WO (1) WO2021127457A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
MX2022007399A (es) 2019-12-20 2022-09-19 Codexis Inc Variantes de alfa-glucosidasa ácida diseñadas.
CN115820609A (zh) * 2022-11-15 2023-03-21 新乡医学院 一种重组琼胶酶及其基因和应用
CN118667797A (zh) * 2023-03-14 2024-09-20 北京据德医药科技有限公司 一种重组酸性α-葡萄糖苷酶及其用途
WO2024231820A1 (en) 2023-05-05 2024-11-14 Takeda Pharmaceutical Company Limited Treatment of pompe disease
JP2026522950A (ja) * 2023-06-30 2026-07-09 クロスウォーク セラピューティクス， インコーポレイテッド 操作された酸アルファ－グルコシダーゼバリアント
WO2025004002A2 (en) 2023-06-30 2025-01-02 Takeda Pharmaceutical Company Limited Treatment of pompe disease
CN117737040B (zh) * 2023-12-08 2025-07-15 深圳市新产业生物医学工程股份有限公司 α-葡萄糖苷酶突变体、试剂盒及其应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
CA2191718A1 (en) 1994-06-03 1995-12-14 Randy M. Berka Phosphonyldipeptides useful in the treatment of cardiovascular diseases
ATE294871T1 (de) 1994-06-30 2005-05-15 Novozymes Biotech Inc Nicht-toxisches, nicht-toxigenes, nicht- pathogenes fusarium expressionssystem und darin zu verwendende promotoren und terminatoren
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
WO1998031816A1 (en) 1997-01-17 1998-07-23 Regents Of The University Of Minnesota Dna molecules and protein displaying improved triazine compound degrading ability
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP1717322B1 (en) 1997-01-17 2012-07-18 Codexis Mayflower Holdings, LLC Evolution of whole cells and organisms by recursive sequence recombination
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
CA2326835A1 (en) 1998-04-02 1999-10-14 Tellus Genetic Resources, Inc. A method for obtaining a plant with a genetic lesion in a gene sequence
CN1314911A (zh) 1998-05-01 2001-09-26 麦克西根股份有限公司 用dna改组优化害虫抗性基因
JP2002517995A (ja) 1998-06-17 2002-06-25 マキシジェン， インコーポレイテッド 所望の特性を有するポリヌクレオチドを生成するための方法
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
EP1104459A1 (en) 1998-08-12 2001-06-06 Maxygen, Inc. Dna shuffling of monooxygenase genes for production of industrial chemicals
AU6510799A (en) 1998-10-07 2000-04-26 Maxygen, Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
EP1129184A1 (en) 1998-11-10 2001-09-05 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US20070065838A1 (en) 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
US7873477B1 (en) 2001-08-21 2011-01-18 Codexis Mayflower Holdings, Llc Method and system using systematically varied data libraries
US8457903B1 (en) 1999-01-19 2013-06-04 Codexis Mayflower Holdings, Llc Method and/or apparatus for determining codons
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
JP2002534965A (ja) 1999-01-19 2002-10-22 マキシジェン， インコーポレイテッド 所望の特徴を有する文字ストリング、ポリヌクレオチドおよびポリペプチドを作製するための方法
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
IL144657A0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
AU3391900A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
SG121902A1 (en) 2000-01-11 2006-05-26 Maxygen Inc Integrated systems for diversity generation and screening
AU4964101A (en) 2000-03-30 2001-10-15 Maxygen Inc In silico cross-over site selection
AU2001249811B2 (en) 2000-04-03 2006-06-08 Maxygen, Inc. Subtilisin variants
WO2003054155A2 (en) 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
EP2315145B1 (en) 2002-03-01 2015-11-25 Codexis Mayflower Holdings, LLC Methods, systems, and software for identifying functional biomolecules
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution
PT1587923E (pt) 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
AU2004263900A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
US20080014188A1 (en) 2004-02-06 2008-01-17 Zankel Todd C Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2009102901A1 (en) 2008-02-12 2009-08-20 Codexis, Inc. Method of generating an optimized, diverse population of variants
US8504498B2 (en) 2008-02-12 2013-08-06 Codexis, Inc. Method of generating an optimized, diverse population of variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
ES2705694T3 (es) 2008-06-13 2019-03-26 Codexis Inc Método de síntesis de variantes de polinucleótidos
WO2010096369A1 (en) 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof
WO2013003290A1 (en) 2011-06-28 2013-01-03 Codexis, Inc. Protein variant generation by region shuffling
EP4062928A3 (en) 2010-02-04 2022-11-30 BioMarin Pharmaceutical Inc. Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
US20150050658A1 (en) 2012-03-15 2015-02-19 Codexix, Inc. Gene shuffling methods
RU2695146C2 (ru) 2013-01-31 2019-07-22 Кодексис, Инк. Способы, системы и программное обеспечение для идентификации биомолекул со взаимодействующими компонентами
DK3049973T3 (en) 2013-09-27 2018-10-22 Codexis Inc AUTOMATED SCREENING OF ENZYM VARIENTS
WO2015048573A1 (en) 2013-09-27 2015-04-02 Codexis, Inc. Structure based predictive modeling
TW201618809A (zh) * 2014-06-13 2016-06-01 維理恩治療公司 用於治療肝醣儲積症及肝醣代謝病症之方法及組合物
MA41022A (fr) * 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
CA2970638A1 (en) * 2014-12-22 2016-06-30 Codexis, Inc. Human alpha-galactosidase variants
IL299470B2 (en) 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
WO2019201855A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Lysosomal fusion protein
SG11202011191WA (en) 2018-05-16 2020-12-30 Spark Therapeutics Inc Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same
MX2022007399A (es) 2019-12-20 2022-09-19 Codexis Inc Variantes de alfa-glucosidasa ácida diseñadas.
JP2026522950A (ja) 2023-06-30 2026-07-09 クロスウォーク セラピューティクス， インコーポレイテッド 操作された酸アルファ－グルコシダーゼバリアント

Also Published As

Publication number Publication date
KR20220129547A (ko) 2022-09-23
IL294082A (en) 2022-08-01
CL2022001655A1 (es) 2023-02-24
JP2025089465A (ja) 2025-06-12
TWI901622B (zh) 2025-10-21
CN115427574A (zh) 2022-12-02
US12497605B2 (en) 2025-12-16
CA3165484A1 (en) 2021-06-24
EP4077679A4 (en) 2024-04-24
CO2022010224A2 (es) 2022-08-09
BR112022011760A2 (pt) 2022-08-30
JP7865532B2 (ja) 2026-05-26
US20240228997A1 (en) 2024-07-11
US11970722B2 (en) 2024-04-30
PE20221266A1 (es) 2022-08-16
JP2023507575A (ja) 2023-02-24
WO2021127457A1 (en) 2021-06-24
MX2022007399A (es) 2022-09-19
AU2020408066A1 (en) 2022-06-30
EP4077679A1 (en) 2022-10-26
TW202136506A (zh) 2021-10-01
US20210189365A1 (en) 2021-06-24
AR120858A1 (es) 2022-03-23

Similar Documents

Publication Publication Date Title
CO2022010224A2 (es) Variantes de alfa-glucosidasa ácida diseñadas por ingeniería
EA201391521A1 (ru) Композиции и способы для ингибирования и/или модулирования эффекторных t-клеток, участвующих в воспалительном нейродегенеративном заболевании
CY1123676T1 (el) Συνθεσεις και μεθοδοι για την εσωτερικοποιηση ενζυμων
BR112013032396A2 (pt) formulações estáveis de aplicações relacionadas à enzima de degradação de ácido hialurônico
CO2019014682A2 (es) Composiciones y métodos para enzimas de internalización
NI200800020A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización.
MX379814B (es) Proceso para preparar compuestos de dihidroisoquinolinas-fenil-purinas.
EA201291073A1 (ru) Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2
MX339624B (es) Composiciones mejoradas de celulas y metodos para preparar las mismas.
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
BR112014018524A2 (pt) derivados de pirimido [4,5-b]indol e métodos de utilização dos mesmos na expansão de células-tronco hematopoiéticas, composição farmacêutica e kits
ECSP12012353A (es) Compuestos, composiciones de tioacetato y métodos de uso
EA201100441A1 (ru) Соединения для коррекции уровня мочевой кислоты и способы их применения
EA201890516A1 (ru) Клинические композиции
CR10345A (es) Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
UY33832A (es) Inhibidores de la faah.
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización